
First Long-Acting Antibody Cocktail to Prevent COVID-19 Submitted for EUA
WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca has submitted a request to the US Food and Drug Administration (FDA) for an Emergency Use Authorization (EUA) for AZD7442, its long-acting antibody (LAAB) combination, for prophylaxis of symptomatic COVID-19. If granted, AZD7442 would be the first LAAB to receive an EUA